Trends in Over-the-Counter Nicotine Replacement Therapy Sales, U.S., 2017–2020
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Trends in Over-the-Counter Nicotine Replacement Therapy Sales, U.S., 2017–2020

Filetype[PDF-178.67 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      Am J Prev Med
    • Personal Author:
    • Description:
      Introduction:

      Few studies have examined trends in over-the-counter U.S. Food and Drug Administration–approved nicotine replacement therapy sales data and consumer preferences for nicotine replacement therapy attributes (e.g., flavor). Examination of consumer preferences may inform both public health smoking cessation programs as well as subsequent research on consumer preferences for potentially reduced-risk tobacco products U.S. Food and Drug Administration may authorize.

      Methods:

      NielsenIQ Retail Measurement Service data were used to examine national trends in over-the-counter nicotine replacement therapy dollar sales from 2017 to 2020 and dollar sales by retail channel and product attributes for the most recent year available at the time of analysis (2020).

      Results:

      Over-the-counter nicotine replacement therapy sales totaled about $1 billion annually between 2017 and 2020. Across the 4-year period, sales of gum and patches decreased, whereas lozenge sales increased (p<0.05 for all). In 2020, gum accounted for 52.7% ($511 million), lozenges accounted for 33.3% ($322 million), and patches accounted for 14.1% ($137 million) of over-the-counter nicotine replacement therapy sales. Drug stores were the retail channel accounting for the largest percentage of total over-the-counter nicotine replacement therapy sales (42.9%). Three leading brands–private label or store brands (62.8%), Nicorette (30.7%,), and NicoDerm CQ (5.7%)–accounted for 99.2% of the total over-the-counter nicotine replacement therapy market. Mint was the most common flavor, representing 41.2% of total gum and 73.6% of total lozenge sales.

      Conclusions:

      This analysis of over-the-counter nicotine replacement therapy sales sheds light on consumer preferences for attributes that can inform efforts to facilitate smoking cessation and research on preferences related to potentially reduced-risk tobacco products.

    • Subjects:
    • Source:
      Am J Prev Med.
    • Pubmed ID:
      36682916
    • Pubmed Central ID:
      PMC10121784
    • Document Type:
      Journal Article
    • Funding:
      CC999999/ImCDC/Intramural CDC HHSUnited States/
    • Place as Subject:
      United States
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov